Dysregulation of Multiple Facets of Glycogen Metabolism in a Murine Model of Pompe Disease

Taylor, Kristin M.; Meyers, Elizabeth; Phipps, Michael; Kishnani, Priya S.; Cheng, Seng H.; Scheule, Ronald K.; Moreland, Rodney J.
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Pompe disease, also known as glycogen storage disease (GSD) type II, is caused by deficiency of lysosomal acid α-glucosidase (GAA). The resulting glycogen accumulation causes a spectrum of disease severity ranging from a rapidly progressive course that is typically fatal by 1 to 2 years of age to a slower progressive course that causes significant morbidity and early mortality in children and adults. The aim of this study is to better understand the biochemical consequences of glycogen accumulation in the Pompe mouse. We evaluated glycogen metabolism in heart, triceps, quadriceps, and liver from wild type and several strains of GAA−/− mice. Unexpectedly, we observed that lysosomal glycogen storage correlated with a robust increase in factors that normally promote glycogen biosynthesis. The GAA−/− mouse strains were found to have elevated glycogen synthase (GS), glycogenin, hexokinase, and glucose-6-phosphate (G-6-P, the allosteric activator of GS). Treating GAA−/− mice with recombinant human GAA (rhGAA) led to a dramatic reduction in the levels of glycogen, GS, glycogenin, and G-6-P. Lysosomal glycogen storage also correlated with a dysregulation of phosphorylase, which normally breaks down cytoplasmic glycogen. Analysis of phosphorylase activity confirmed a previous report that, although phosphorylase protein levels are identical in muscle lysates from wild type and GAA−/− mice, phosphorylase activity is suppressed in the GAA−/− mice in the absence of AMP. This reduction in phosphorylase activity likely exacerbates lysosomal glycogen accumulation. If the dysregulation in glycogen metabolism observed in the mouse model of Pompe disease also occurs in Pompe patients, it may contribute to the observed broad spectrum of disease severity.


Related Articles

  • Structural and biochemical studies on Pompe disease and a “pseudodeficiency of acid α-glucosidase”. Tajima, Youichi; Matsuzawa, Fumiko; Aikawa, Sei-ichi; Okumiya, Toshika; Yoshimizu, Michiru; Tsukimura, Takahiro; Ikekita, Masahiko; Tsujino, Seiichi; Tsuji, Akihiko; Edmunds, Tim; Sakuraba, Hitoshi // Journal of Human Genetics;Nov2007, Vol. 52 Issue 11, p898 

    We constructed structural models of the catalytic domain and the surrounding region of human wild-type acid α-glucosidase and the enzyme with amino acid substitutions by means of homology modeling, and examined whether the amino acid replacements caused structural and biochemical changes in...

  • Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease. Yunxiang Zhu; Ji-Lei Jiang; Gumlaw, Nathan K.; Jinhua Zhang; Bercury, Scott D.; Ziegler, Robin J.; Lee, Karen; Kudo, Mariko; Canfield, William M.; Edmunds, Timothy; Jiang, Canwen; Mattaliano, Robert J.; Cheng, Seng H. // Molecular Therapy;Jun2009, Vol. 17 Issue 6, p954 

    Improving the delivery of therapeutics to disease-affected tissues can increase their efficacy and safety. Here, we show that chemical conjugation of a synthetic oligosaccharide harboring mannose 6-phosphate (M6P) residues onto recombinant human acid α-glucosidase (rhGAA) via oxime chemistry...

  • Production of a Functional Human Acid Maltase in Tobacco Seeds: Biochemical Analysis, Uptake by Human GSDII Cells, and In Vivo Studies in GAA Knockout Mice. Martiniuk, Frank; Reggi, Serena; Tchou-Wong, Kam-Meng; Rom, William; Busconi, Matteo; Fogher, Corrado // Applied Biochemistry & Biotechnology;Oct2013, Vol. 171 Issue 4, p916 

    Genetic deficiency of acid alpha glucosidase (GAA) results in glycogen storage disease type II (GSDII) or Pompe's disease. To investigate whether we could generate a functional recombinant human GAA enzyme (tobrhGAA) in tobacco seeds for future enzyme replacement therapy, we subcloned the human...

  • Infantile Pompe Disease: Clinical and Genetic Characteristics With an Experience of Enzyme Replacement Therapy. Cho, Anna; Kim, Su Jin; Lim, Byung Chan; Hwang, Hee; Park, June Dong; Kim, Gi Beom; Jin, Dong-Kyu; Lee, Jeehun; Ki, Chang Seok; Kim, Ki Joong; Hwang, Yong Seung; Chae, Jong-Hee // Journal of Child Neurology;Mar2012, Vol. 27 Issue 3, p319 

    Pompe disease is an autosomal recessive disorder caused by lysosomal acid α-glucosidase deficiency. Infantile-onset Pompe disease presents with cardiomyopathy and hypotonia, leading to premature death. This article describes 7 infantile Pompe disease cases and provides their molecular bases...

  • Three years experience with dried blood spot α-glucosidase screening for Pompe disease in British Columbia, Canada. Horvath, Gabriella; Sirrs, Sandra; Stockler, Sylvia; Salvarinova-Zivkovic, Ramona; Vallance, Hilary; Waters, Paula // BMC Musculoskeletal Disorders;2013, Vol. 14 Issue Suppl 2, pP2 

    An abstract of the article "Three years experience with dried blood spot α-glucosidase screening for Pompe disease in British Columbia, Canada" by Gabriella Horvath, Sandra Sirrs, Sylvia Stockler, Ramona Salvarinova-Zivkovic, Hilary Vallance and Paula Waters is presented.

  • Autophagy and Mistargeting of Therapeutic Enzyme in Skeletal Muscle in Pompe Disease. Fukuda, Tokiko; Ahearn, Meghan; Roberts, Ashley; Mattaliano, Robert J.; Zaal, Kristien; Ralston, Evelyn; Plotz, Paul H.; Raben, Nina // Molecular Therapy;Dec2006, Vol. 14 Issue 6, p831 

    Enzyme replacement therapy (ERT) became a reality for patients with Pompe disease, a fatal cardiomyopathy and skeletal muscle myopathy caused by a deficiency of glycogen-degrading lysosomal enzyme acid α-glucosidase (GAA). The therapy, which relies on receptor-mediated endocytosis of...

  • Gel-mediated Delivery of AAV1 Vectors Corrects Ventilatory Function in Pompe Mice With Established Disease. Mah, Cathryn S.; Falk, Darin J.; Germain, Sean A.; Kelley, Jeffry S.; Lewis, Melissa A.; Cloutier, Denise A.; DeRuisseau, Lara R.; Conlon, Thomas J.; Cresawn, Kerry O.; Fraites, Jr., Thomas J.; Campbell-Thompson, Martha; Fuller, David D.; Byrne, Barry J. // Molecular Therapy;Mar2010, Vol. 18 Issue 3, p502 

    Pompe disease is a muscular dystrophy that results in respiratory insufficiency. We characterized the outcomes of targeted delivery of recombinant adeno-associated virus serotype 1 (rAAV2/1) vector to diaphragms of Pompe mice with varying stages of disease progression. We observed significant...

  • Physiological Correction of Pompe Disease by Systemic Delivery of Adeno-associated Virus Serotype 1 Vectors. Mah, Cathryn; Pacak, Christina A; Cresawn, Kerry O; DeRuisseau, Lara R; Germain, Sean; Lewis, Melissa A; Cloutier, Denise A; Fuller, David D; Byrne, Barry J // Molecular Therapy;Mar2007, Vol. 15 Issue 3, p501 

    Pompe disease is caused by a lack of functional lysosomal acid α-glucosidase (GAA) and can ultimately lead to fatal hypertrophic cardiomyopathy and respiratory insufficiency. Previously, we demonstrated the ability of recombinant adeno-associated virus serotype 1 (rAAV2/1) vector to restore...

  • Evidence of cardiomyocyte necrosis in glycogen storage disease type II. Gaze, David C.; Lawson, Graham J.; Harris, Adam; Collinson, Paul O. // Annals of Clinical Biochemistry;Jan2007, Vol. 44 Issue 1, p86 

    Adult-onset glycogen storage disease type II (GSD-II), unlike the infantile form, is not normally associated with coexisting cardiovascular pathologies. In infantile onset GSD-II, cardiomyopathy is a common feature, and mutations in the genes for cardiac troponin T and I are likely to be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics